OCT-Angiography (OCT-A) for AMD

OCT-Angiography works by capturing thousands of rapid scans of your retina and comparing them to detect movement. OCT-A detects motion signal largely from blood flow, but image quality can be affected by eye movement and other artifacts. The computer can create a three-dimensional map of your retinal circulation in seconds while you look at a target light.

The technology separates different layers of your retina, allowing our eye doctor to see where abnormal vessels have blood flow. Leakage and fluid are assessed with standard OCT and sometimes dye angiography. These detailed maps help us spot problems before they damage your vision permanently.

Standard OCT takes cross-sectional pictures of your retina to show its structure and thickness, much like an ultrasound creates images of a developing baby. OCT-A uses similar technology but adds motion detection to reveal blood flow. Both tests are often performed together during the same visit.

• Standard OCT shows retinal layers and detects fluid or swelling
• OCT-A highlights blood vessels and reveals areas of poor circulation
• Neither test requires injections or physical contact with your eye
• Both provide immediate results that help guide your care plan

In wet AMD, abnormal blood vessels grow beneath your retina and can leak fluid or bleed, causing rapid vision loss. In dry AMD, multiple mechanisms including drusen accumulation, retinal cell dysfunction, and changes in circulation contribute to vision decline. OCT-A can help localize abnormal blood flow patterns, while structural OCT and clinical examination determine whether fluid or bleeding is present.

By mapping your retinal blood flow, we can detect new vessel formation, monitor changes in existing vessel networks, and identify areas where circulation is declining. This information, combined with structural imaging, shapes every treatment decision we make.

Traditional fluorescein angiography requires injecting dye into your arm and taking photographs as it circulates through your eye. While still valuable in some cases, it carries small risks of nausea, allergic reactions, or skin discoloration. OCT-A gives us complementary information without needles or dye.

• No injection means no risk of allergic reaction or side effects
• Faster completion with immediate digital results
• Better visualization of deeper retinal layers
• Easier to repeat frequently for close monitoring
• More comfortable for patients who dislike needles

While OCT-A is a valuable tool, it has some limitations that your eye doctor considers when planning your care. Understanding these helps explain why we sometimes recommend additional testing.

• Motion artifacts and segmentation errors can reduce image accuracy
• Media opacity from cataracts, dry eye, or hemorrhage can obscure results
• Limited field of view may miss peripheral retinal changes
• OCT-A does not show dye leakage or staining, so fluorescein or other angiography may still be needed in some cases
• Very slow blood flow can be underestimated or missed entirely

When OCT-A reveals new abnormal blood vessels, we typically recommend anti-VEGF injections to reduce their activity and prevent further damage. These medications, delivered directly into your eye, have become the standard treatment for wet AMD in 2025. The frequency of injections depends on how your condition responds.

OCT-A helps us measure the area of abnormal vessels before treatment and track changes afterward. If structural OCT shows reduced fluid and scans suggest decreased neovascular activity, we may space out your injections. If findings suggest ongoing activity despite treatment, we may adjust the medication type or injection schedule.

For dry AMD, OCT-A shows us regions of decreasing blood flow and retinal thinning. No treatment restores lost vision from dry AMD, but for geographic atrophy there are FDA-approved complement inhibitor injections that can slow lesion growth in selected patients. We monitor these changes carefully because areas of poor circulation might develop new vessel growth.

Geographic atrophy treatment involves regular injections and careful monitoring, and the effect is slowing progression rather than improvement. Not all patients with dry AMD are candidates, and the decision involves balancing treatment burden with potential benefit. For intermediate dry AMD, certain AREDS2 vitamin formulations may help slow progression, though they are not appropriate for everyone. Your eye doctor will discuss whether these options fit your specific situation.

If OCT-A detects early signs that dry AMD might convert to wet AMD, we will increase your monitoring frequency. Catching the conversion within days or weeks of onset gives us the best chance to preserve your reading and driving vision with prompt treatment.

Your OCT-A results guide whether we recommend starting treatment, continuing current therapy, or switching approaches. For active wet AMD, treatment is usually urgent and ongoing. For dry AMD with high-risk features, we might suggest specific vitamins and closer monitoring. For stable or very early changes, observation with regular imaging may be appropriate.

• New or worsening exudation is typically treated promptly, often within days to a couple of weeks, depending on severity and findings
• Stable wet AMD on treatment continues with scheduled injections
• High-risk dry AMD may benefit from AREDS2 vitamin formulations
• Early or low-risk changes warrant monitoring every six to twelve months

At home, use an Amsler grid daily to check for new distortion or blind spots. This simple test involves looking at a page with a grid of lines while covering one eye. If the lines become wavy or areas disappear, contact our office before your next scheduled visit. Good lighting and magnifiers can help you read and perform daily tasks more comfortably.

Protect your macula by not smoking, eating leafy greens and fish, wearing sunglasses outdoors, and managing your blood pressure and cholesterol. These habits support the health of your retinal blood vessels and may slow AMD progression. Take any prescribed vitamins consistently as directed.

Patients with wet AMD receiving injections often have OCT-A scans at every visit, which might be monthly or every few months depending on your treatment regimen. Those with dry AMD might have scans every six to twelve months to watch for progression. Your individual schedule depends on the severity of your disease and how quickly it has changed in the past.

OCT-A imaging is generally considered safe, and your eye doctor will balance the benefits with visit burden and clinical need. If you experience new symptoms between scheduled visits, we will bring you in sooner for additional imaging to check for changes that need immediate attention.

Call our office immediately if you notice sudden new distortion, a shadow or dark spot in your central vision, a sudden decrease in your ability to read or recognize faces, or if straight lines suddenly look bent. These changes may indicate active leakage or new vessel growth requiring urgent treatment.

• Sudden worsening of distortion when using your Amsler grid
• New blank areas in your central vision
• Rapid decline in reading vision over days to weeks
• Increase in blurriness that new glasses do not fix
• Any sudden vision loss or curtain-like shadow